Emv Capital (EMVC) RNS Announcements

Add to Alert list
Date Time Source Announcement
01 Feb 2023 07:00 AM
RNS
Board Change
03 Jan 2023 01:31 PM
RNS
PDS Announces Exclusive Global License Agreement
28 Dec 2022 03:05 PM
RNS
PDS Biotech: Median Overall Survival announcement
16 Dec 2022 07:00 AM
RNS
PDS: HPV16 Head and Neck Cancer announcement
12 Dec 2022 02:00 PM
RNS
Board Changes; Options; Co-Investment Agreement
29 Nov 2022 07:00 AM
RNS
EMV C leads £4.2m round in 5G and SATCOM leader
14 Nov 2022 02:50 PM
RNS
PDS Q3 Results and Business Update
14 Nov 2022 02:05 PM
RNS
Second Price Monitoring Extn
14 Nov 2022 02:00 PM
RNS
Price Monitoring Extension
09 Nov 2022 07:00 AM
RNS
Board Change
07 Nov 2022 03:40 PM
RNS
PDS reports presentation of data at cancer society
20 Oct 2022 07:00 AM
RNS
EMV Capital secures investment in Ventive
11 Oct 2022 04:00 PM
RNS
PDS Update
03 Oct 2022 01:56 PM
RNS
PDS completes End-of-Phase 2 meeting with FDA
30 Sep 2022 07:00 AM
RNS
Half-year Report
25 Aug 2022 07:00 AM
RNS
PDS Completes $35 Million Financing Agreement
16 Aug 2022 07:00 AM
RNS
Acquisition of 30% Vortex stake & new Vortex CEO
08 Aug 2022 04:45 PM
RNS
PDS Reports Q2 2022 Results & Business Update
29 Jun 2022 02:05 PM
RNS
Result of AGM
28 Jun 2022 09:15 AM
RNS
Holding(s) in Company
27 Jun 2022 08:30 AM
RNS
Holding(s) in Company
27 Jun 2022 08:30 AM
RNS
Director/PDMR Shareholding
22 Jun 2022 07:00 AM
RNS
Result of Placing and Total Voting Rights
21 Jun 2022 04:41 PM
RNS
Proposed Placing to raise at least £1.5 million
17 Jun 2022 12:00 PM
RNS
NetScientific to increase Q-Bot stake to 23.7%
15 Jun 2022 07:00 AM
RNS
Q-Bot secures £1.6m of investment to fund growth
07 Jun 2022 11:07 AM
RNS
Notice of AGM and Annual Report & Accounts
06 Jun 2022 07:00 AM
RNS
PDS Granted FDA Fast Track Designation for PDS0101
27 May 2022 02:39 PM
RNS
PDS Biotech - new data for ongoing clinical trials
19 May 2022 07:00 AM
RNS
General Counsel Strategic Hire & Grant of Options
16 May 2022 07:00 AM
RNS
ProAxsis Update
12 May 2022 07:00 AM
RNS
Final Results
11 May 2022 03:46 PM
RNS
PDS Reports Q1 2022 Results & Business Update
09 May 2022 07:00 AM
RNS
Notice of Results & Investor Presentation
06 May 2022 07:00 AM
RNS
Acquisition of 30% of Vortex Biotech Holdings
25 Apr 2022 02:05 PM
RNS
Second Price Monitoring Extn
25 Apr 2022 02:00 PM
RNS
Price Monitoring Extension
25 Apr 2022 11:05 AM
RNS
Second Price Monitoring Extn
25 Apr 2022 11:00 AM
RNS
Price Monitoring Extension
31 Mar 2022 01:24 PM
RNS
PDS Provides Business Update & Full-Year Results
04 Mar 2022 07:30 AM
RNS
Publication of Shareholder Newsletter
24 Feb 2022 04:45 PM
RNS
PDS Announces Preliminary Safety Data on PDS0101
15 Feb 2022 02:32 PM
RNS
PDS Clinical Trial with Mayo Clinic
02 Feb 2022 03:00 PM
RNS
PDS Phase 2 Trial Update
28 Jan 2022 08:45 AM
RNS
PDS Announces Preclinical Data for PDS0202 Vaccine
18 Jan 2022 07:00 AM
RNS
Holding(s) in Company
10 Jan 2022 02:20 PM
RNS
PDS Granted Novel HPV16 Immunotherapy Patent
10 Jan 2022 07:00 AM
RNS
ProAxsis CEO End of Year Update
29 Dec 2021 08:47 AM
RNS
Issue of Equity
21 Dec 2021 01:59 PM
RNS
TR-1: Form for notification of major holdings

EMV Capital is a London venture capital company that invests in early-stage, IP-rich, technology and life sciences companies in the UK and internationally.

It is listed on AIM under the ticker EMVC.

EMVC share price launched at 1,620p in 2013.

UK 100

Latest directors dealings